452 related articles for article (PubMed ID: 21455237)
1. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.
Leiper J; Nandi M
Nat Rev Drug Discov; 2011 Apr; 10(4):277-91. PubMed ID: 21455237
[TBL] [Abstract][Full Text] [Related]
2. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.
Wadham C; Mangoni AA
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):303-19. PubMed ID: 19331593
[TBL] [Abstract][Full Text] [Related]
3. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase.
Ueda S; Kato S; Matsuoka H; Kimoto M; Okuda S; Morimatsu M; Imaizumi T
Circ Res; 2003 Feb; 92(2):226-33. PubMed ID: 12574151
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine.
Sharma S; Smith A; Kumar S; Aggarwal S; Rehmani I; Snead C; Harmon C; Fineman J; Fulton D; Catravas JD; Black SM
Vascul Pharmacol; 2010; 52(5-6):182-90. PubMed ID: 19962451
[TBL] [Abstract][Full Text] [Related]
6. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.
Pope AJ; Karrupiah K; Kearns PN; Xia Y; Cardounel AJ
J Biol Chem; 2009 Dec; 284(51):35338-47. PubMed ID: 19820234
[TBL] [Abstract][Full Text] [Related]
7. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
8. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Yamagishi S; Ueda S; Nakamura K; Matsui T; Okuda S
Curr Pharm Des; 2008; 14(25):2613-8. PubMed ID: 18991678
[TBL] [Abstract][Full Text] [Related]
9. The DDAH-ADMA-NOS pathway.
Leiper JM
Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons.
Selley ML
J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741
[TBL] [Abstract][Full Text] [Related]
11. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
Dayoub H; Rodionov RN; Lynch C; Cooke JP; Arning E; Bottiglieri T; Lentz SR; Faraci FM
Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes.
Yokoro M; Suzuki M; Murota K; Otsuka C; Yamashita H; Takahashi Y; Tsuji H; Kimoto M
Biosci Biotechnol Biochem; 2012; 76(7):1334-42. PubMed ID: 22785485
[TBL] [Abstract][Full Text] [Related]
14. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Palm F; Onozato ML; Luo Z; Wilcox CS
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
Aldámiz-Echevarría L; Andrade F
Int J Mol Sci; 2012; 13(9):11288-11311. PubMed ID: 23109853
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
18. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
Leiper J; Vallance P
Cardiovasc Res; 1999 Aug; 43(3):542-8. PubMed ID: 10690326
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological activation of dimethylarginine dimethylaminohydrolase (DDAH) activity by inorganic nitrate and DDAH inhibition by N
Bollenbach A; Tsikas D
Amino Acids; 2019 Mar; 51(3):483-494. PubMed ID: 30536052
[TBL] [Abstract][Full Text] [Related]
20. ADMA metabolism and clearance.
Teerlink T
Vasc Med; 2005 Jul; 10 Suppl 1():S73-81. PubMed ID: 16444872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
